Discrepant factor VIII activity in a family with mild haemophilia A and Arg531His mutation using various FVIII assays and APTT reagents [2]

Haemophilia

Volumn 11, Issue 5, 2005, Pages 561-564

  Lucia J F ^a   Aguilar, Carlos ^b   Dobon, M ^a   Aznar, J A ^c   Tizano, E ^d   Bores C ^e   Cornudella, R ^f   Calvo, M T ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b Hospital General Santa Barbara   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e Dade Behring SA   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ARGININE; BLOOD CLOTTING FACTOR 8; FRESH FROZEN PLASMA; HISTAMINE; REAGENT;

ABDOMINAL BLEEDING; ADULT; BLEEDING DISORDER; BRAIN HEMORRHAGE; CASE REPORT; CLINICAL FEATURE; ENZYME ASSAY; ERYTHROCYTE TRANSFUSION; EXON; FAMILY STUDY; HEMOPHILIA A; HUMAN; INTERVERTEBRAL DISK HERNIA; LABORATORY TEST; LETTER; MALE; MEDICAL ASSESSMENT; MISSENSE MUTATION; PARTIAL THROMBOPLASTIN TIME; PATIENT REFERRAL; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

ADULT; FACTOR VIII; HEMOPHILIA A; HUMANS; MALE; MUTATION, MISSENSE; PARTIAL THROMBOPLASTIN TIME; PEDIGREE;

EID: 24644523566     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01122.x     Document Type: Letter

References (17)

1. Lazarchick J, Hoyer LW. Immunoradiometric measurement of the factor VIII procoagulant antigen. J Clin Invest 1978; 62: 1048-52.
2. Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94: 400-6.
3. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87: 846-8.
4. Pipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001; 97: 685-91.
5. Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Haemost 2003; 29: 23-30.
6. Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999; 93: 176-83.
7. Robinson AJ, Aggeler PM, McNicol GP, Douglas AS. An atypical genetic haemorrhagic disease with increased concentration of a natural inhibitor of prothrombin consumption. Br J Haematol 1967; 13: 510-27.
8. Hakeos WH, Miao H, Sirachainan N et al. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thromb Haemost 2002; 88: 781-7.
9. Mumford AD, Laffan M, O'Donnell J et al. A Tyr → Cys substitution in the interdomain acidic region A1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol 2002; 118: 589-94.
10. Schwaab R, Oldenburg J, Kemball-Cook G et al. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 2000; 109: 523-8.
11. Barrowcliffe TV. Comparisons of one-stage and two-stage assays of factor VIII:C. Scand J Haematol 1984; 33(Suppl. 41): 39-54.
12. Barrowcliffe TW. The one-stage versus two-stage factor VIII assay. In: Triplett DA, ed. Advances in Coagulation Testing. Skokie, IL: College of American Pathologists, 1986: 47-62.
13. Hubbard AR, Curtis AD, Barrowcliffe TV, Edwards SJ, Jennings CA, Kemball-Cook G. Assay of factor VIII concentrates: comparison of chromogenic and two-stage clotting assays. Thromb Res 1986; 44: 887-91.
14. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization and recommendations. Semin Thromb Haemost 2002; 28: 247-55.
15. Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 1978-84.
16. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidyl-serine. Blood 1990; 75: 1994-2004.
17. Rosen S. Assay of factor VIII:C with a chromogenic substrate. Scand J Haematol 1984; 40(Suppl.): 139-45.